Peter DeMuth, Ph.D.

Peter DeMuth, Ph.D.

Chief Scientific OfficeratElicio Therapeutics· In proxies 2023–2024

Pay in FY2024+72% from the year before · Elicio Therapeutics stock -38.8% the same year

Peter DeMuth, Ph.D. was paid $866.7K in FY2024 (Dec), up 72%. Elicio Therapeutics stock fell 38.8% that year.

Pay$100 in the stock at the end of FY22 → $63
Pay is from the Summary Compensation Table of each Elicio Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Elicio TherapeuticsPublic company · 3 yr
    • Chief Scientific Officer2023 – Present · 3 yrStock in role -78%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?